Thienopyridines: Time for Personalized Therapy?

JACC: Cardiovascular Interventions

Volumn 1, Issue 6, 2008, Pages 718-719

  King III, Spencer B ^b   Momary, Kathryn M ^a  

^a MERCER UNIVERSITY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; CANGRELOR; CLOPIDOGREL; PRASUGREL; THIENOPYRIDINE DERIVATIVE; WARFARIN;

ARTERY THROMBOSIS; BLEEDING; CLINICAL TRIAL; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG ELUTING STENT; DRUG HALF LIFE; DRUG SAFETY; EDITORIAL; ENDOTHELIUM; HEALING; HUMAN; PATIENT CARE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RESTENOSIS; STANDARD; THROMBOCYTE FUNCTION;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; DRUG THERAPY, COMBINATION; HUMANS; PATIENT SELECTION; PLATELET AGGREGATION INHIBITORS; PRACTICE GUIDELINES AS TOPIC; PYRIDINES; RISK ASSESSMENT; STENTS; THROMBOSIS; TREATMENT OUTCOME;

EID: 57549091816     PISSN: 19368798     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcin.2008.10.003     Document Type: Editorial

References (6)

1. Thornton M.A., Gruentzig A.R., Hollman J., King III S.B., and Douglas J.S. Coumadin and aspirin in prevention of recurrence after transluminal coronary angioplasty: a randomized study. Circulation 69 (1984) 721-727
2. King III S.B., Smith Jr. S.C., Hirshfeld Jr. J.W., Jacobs A.K., Morrison D.A., and Williams D.O. 2007 focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: (2007 Writing Group to Review New Evidence and Update the 2005 ACC/AHA/SCAI Guideline Update for Percutaneous Coronary Intervention). J Am Coll Cardiol 51 (2008) 172-209
3. Gladding P., Webster M., Ormiston J., Olsen S., and White H. Antiplatelet drug nonresponsiveness. Am Heart J 155 (2008) 591-599
4. Gladding P., Webster M., Zeng I., et al. The antiplatelet effect of higher loading and maintenance dose regimens of clopidogrel: the PRINC (Plavix Response in Coronary Intervention) trial. J Am Coll Cardiol Intv 1 (2008) 612-619
5. Gladding P., Webster M., Zeng I., et al. The pharmacogenetics and pharmacodynamics of clopidogrel response: an analysis from the PRINC (Plavix Response in Coronary Intervention) trial. J Am Coll Cardiol Intv 1 (2008) 620-627
6. Aleil B., Jacquemin L., De Poli F., et al. Clopidogrel 150 mg/day to overcome low responsiveness in patients undergoing elective percutaneous coronary intervention. results from the VASP-02 (Vasodilator-Stimulated Phosphoprotein-02) randomized study. J Am Coll Cardiol Intv 1 (2008) 631-638